Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231058 | 0.95 | — | — | |
| SCHEMBL17029461 | 0.93 | MEN1 (0.52) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL18364665 | 0.93 | MEN1 (0.52) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL15264130 | 0.93 | MEN1 (0.52) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL29002323 | 0.91 | MEN1 (0.50) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| Di(Hydroxyethyl)Ether SCHEMBL7553011 | 0.83 | TSHR (0.59) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL6236876 | 0.83 | CYP2C19 (0.47) | TSHRMEN1KMT2AHTTCYP2C19 | |
| SCHEMBL6130652 | 0.82 | MEN1 (0.47) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL15836190 | 0.82 | TSHR (0.56) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL4392298 | 0.82 | TSHR (0.44) | TSHRMAPK1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009938-A1 | Methods of enhancing renal uptake of oligonucleotides | ISIS PHARMACEUTICAL INC. | 2004-01-15 | — | — | US | disclosed |
| US-6600032-B1 | Compound for use in the treatment of viral, protozoan and parasitic infections | ISIS PHARMACEUTICALS, INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1102787-A1 | 2'-O-AMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008044-A1 | 2'-O-AMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009938-A1 | Methods of enhancing renal uptake of oligonucleotides | NUDT1, SLC29A2, DUT | TSHR 1259/4885MAPK1 4788/4885ALDH1A1 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.